117960-27-7

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 586-77-6 4-bromo-N,N-dimethylaniline 

Downstream Products

• 117960-32-4 7-(4-Dimethylamino-phenyl)-1-methyl-3-oxo-2,3,5,6,7,8-hexahydro-isoquinoline-4-carbonitrile 
• 117960-55-1 2-Acetyl-4-(4-dimethylamino-phenyl)-cyclohexanone 
• 117960-49-3 4-<4-(dimethylamino)phenyl>cyclohexanone 
• 117960-52-8 4-<4-(dimethylamino)phenyl>cyclohexen-1-one 

Relevant academic research and scientific papers

4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I): wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Cardiotonic Agents. 1-Methyl-7-(4-pyridyl)-5,6,7,8-tetrahydro-3(2H)-isoquinolinones and Related Compounds. Synthesis and Activity

A series of 1-methyl-7-(4-pyridyl)-5,6,7,8-tetrahydro-3(2H)-isoquinolinones and related compounds were synthesized and evaluated for positive inotropic activity.Most members of this series exerted a dose-dependent increase in myocardial contractility in the dog acute heart failure model, whereas they caused only slight changes in heart rate and blood pressure.Several derivatives, especially those with cyano, acetyl, and ethyl substituents at the 4-position, were more potent than milrinone, which was used as a reference. 4-Acetyl-1-methyl-7-(4-pyridyl)-5,6,7,8-tetrahydro-3(2H)-isoquinolinone (MS-857) is one of the most potent positive inotropic agents in this series.